Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28121189 | 0.83 | MTNR1A (0.50) | OPRM1OPRD1OPRK1HPGDALDH1A1 | |
| SCHEMBL28121194 | 0.80 | HPGD (0.59) | OPRM1OPRD1OPRK1HPGDALDH1A1 | |
| SCHEMBL7516052 | 0.79 | KDM4E (0.56) | LMNAOPRM1OPRD1OPRK1TDP1 | |
| SCHEMBL28121192 | 0.79 | HPGD (0.51) | OPRM1OPRD1OPRK1HPGDALDH1A1 | |
| SCHEMBL6956890 | 0.78 | SPR (0.70) | SPRMAPK1LMNAPTPN1ALDH1A1 | |
| SCHEMBL3650795 | 0.77 | OPRM1 (0.51) | OPRM1OPRD1OPRK1HPGDALDH1A1 | |
| SCHEMBL28453156 | 0.77 | OPRM1 (0.44) | OPRM1OPRD1OPRK1TDP1HPGD | |
| SCHEMBL392452 | 0.76 | GLA (0.58) | LMNAOPRM1OPRD1OPRK1HPGD | |
| SCHEMBL9373709 | 0.76 | TAAR1 (0.50) | OPRM1OPRD1OPRK1TDP1HPGD | |
| SCHEMBL7332349 | 0.75 | OPRM1 (0.43) | OPRM1OPRD1OPRK1TDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309542-B2 | Substituted pyrrolidine amides, the production thereof, and the use thereof as medications | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| EP-2132193-B1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | DDC, GLS, UROD | SPR 1753/4885MAPK1 2494/4885LMNA 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.